258 related articles for article (PubMed ID: 17404085)
1. Promoter hypermethylation identifies progression risk in bladder cancer.
Yates DR; Rehman I; Abbod MF; Meuth M; Cross SS; Linkens DA; Hamdy FC; Catto JW
Clin Cancer Res; 2007 Apr; 13(7):2046-53. PubMed ID: 17404085
[TBL] [Abstract][Full Text] [Related]
2. Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection.
Hoque MO; Begum S; Topaloglu O; Chatterjee A; Rosenbaum E; Van Criekinge W; Westra WH; Schoenberg M; Zahurak M; Goodman SN; Sidransky D
J Natl Cancer Inst; 2006 Jul; 98(14):996-1004. PubMed ID: 16849682
[TBL] [Abstract][Full Text] [Related]
3. Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma.
Catto JW; Azzouzi AR; Rehman I; Feeley KM; Cross SS; Amira N; Fromont G; Sibony M; Cussenot O; Meuth M; Hamdy FC
J Clin Oncol; 2005 May; 23(13):2903-10. PubMed ID: 15753461
[TBL] [Abstract][Full Text] [Related]
4. Ras association domain family 1A: a promising prognostic marker in recurrent nonmuscle invasive bladder cancer.
Kim JS; Chae Y; Ha YS; Kim IY; Byun SS; Yun SJ; Kim WJ
Clin Genitourin Cancer; 2012 Jun; 10(2):114-20. PubMed ID: 22382007
[TBL] [Abstract][Full Text] [Related]
5. Promoter hypermethylation in tumour suppressor genes shows association with stage, grade and invasiveness of bladder cancer.
Jarmalaite S; Jankevicius F; Kurgonaite K; Suziedelis K; Mutanen P; Husgafvel-Pursiainen K
Oncology; 2008; 75(3-4):145-51. PubMed ID: 18824877
[TBL] [Abstract][Full Text] [Related]
6. High promoter methylation levels of APC predict poor prognosis in sextant biopsies from prostate cancer patients.
Henrique R; Ribeiro FR; Fonseca D; Hoque MO; Carvalho AL; Costa VL; Pinto M; Oliveira J; Teixeira MR; Sidransky D; Jerónimo C
Clin Cancer Res; 2007 Oct; 13(20):6122-9. PubMed ID: 17947477
[TBL] [Abstract][Full Text] [Related]
7. Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy.
Rosenbaum E; Hoque MO; Cohen Y; Zahurak M; Eisenberger MA; Epstein JI; Partin AW; Sidransky D
Clin Cancer Res; 2005 Dec; 11(23):8321-5. PubMed ID: 16322291
[TBL] [Abstract][Full Text] [Related]
8. Evidence for the early onset of aberrant promoter methylation in urothelial carcinoma.
Dhawan D; Hamdy FC; Rehman I; Patterson J; Cross SS; Feeley KM; Stephenson Y; Meuth M; Catto JW
J Pathol; 2006 Jul; 209(3):336-43. PubMed ID: 16639696
[TBL] [Abstract][Full Text] [Related]
9. Interest of methylated genes as biomarkers in urothelial cell carcinomas of the urinary tract.
Phé V; Cussenot O; Rouprêt M
BJU Int; 2009 Oct; 104(7):896-901. PubMed ID: 19522860
[TBL] [Abstract][Full Text] [Related]
10. Methylation of the RUNX3 promoter as a potential prognostic marker for bladder tumor.
Kim EJ; Kim YJ; Jeong P; Ha YS; Bae SC; Kim WJ
J Urol; 2008 Sep; 180(3):1141-5. PubMed ID: 18639281
[TBL] [Abstract][Full Text] [Related]
11. p16INK4a and p14ARF methylation as a potential biomarker for human bladder cancer.
Kawamoto K; Enokida H; Gotanda T; Kubo H; Nishiyama K; Kawahara M; Nakagawa M
Biochem Biophys Res Commun; 2006 Jan; 339(3):790-6. PubMed ID: 16316628
[TBL] [Abstract][Full Text] [Related]
12. Combination analysis of hypermethylated Wnt-antagonist family genes as a novel epigenetic biomarker panel for bladder cancer detection.
Urakami S; Shiina H; Enokida H; Kawakami T; Kawamoto K; Hirata H; Tanaka Y; Kikuno N; Nakagawa M; Igawa M; Dahiya R
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2109-16. PubMed ID: 16609023
[TBL] [Abstract][Full Text] [Related]
13. Value of p16INK4a and RASSF1A promoter hypermethylation in prognosis of patients with resectable non-small cell lung cancer.
Wang J; Lee JJ; Wang L; Liu DD; Lu C; Fan YH; Hong WK; Mao L
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6119-25. PubMed ID: 15447998
[TBL] [Abstract][Full Text] [Related]
14. Methylation patterns of Rb1 and Casp-8 promoters and their impact on their expression in bladder cancer.
Malekzadeh K; Sobti RC; Nikbakht M; Shekari M; Hosseini SA; Tamandani DK; Singh SK
Cancer Invest; 2009 Jan; 27(1):70-80. PubMed ID: 19160091
[TBL] [Abstract][Full Text] [Related]
15. Comparative promoter methylation analysis of p53 target genes in urogenital cancers.
Christoph F; Hinz S; Weikert S; Kempkensteffen C; Schostak M; Miller K; Schrader M
Urol Int; 2008; 80(4):398-404. PubMed ID: 18587251
[TBL] [Abstract][Full Text] [Related]
16. RUNX3 methylation as a predictor for disease progression in patients with non-muscle-invasive bladder cancer.
Yan C; Kim YW; Ha YS; Kim IY; Kim YJ; Yun SJ; Moon SK; Bae SC; Kim WJ
J Surg Oncol; 2012 Mar; 105(4):425-30. PubMed ID: 22311819
[TBL] [Abstract][Full Text] [Related]
17. Promoter hypermethylation of multiple genes in early gastric adenocarcinoma and precancerous lesions.
Zou XP; Zhang B; Zhang XQ; Chen M; Cao J; Liu WJ
Hum Pathol; 2009 Nov; 40(11):1534-42. PubMed ID: 19695681
[TBL] [Abstract][Full Text] [Related]
18. N-cadherin as a novel prognostic marker of progression in superficial urothelial tumors.
Lascombe I; Clairotte A; Fauconnet S; Bernardini S; Wallerand H; Kantelip B; Bittard H
Clin Cancer Res; 2006 May; 12(9):2780-7. PubMed ID: 16675571
[TBL] [Abstract][Full Text] [Related]
19. Identification of PMF1 methylation in association with bladder cancer progression.
Aleman A; Cebrian V; Alvarez M; Lopez V; Orenes E; Lopez-Serra L; Algaba F; Bellmunt J; López-Beltrán A; Gonzalez-Peramato P; Cordon-Cardo C; García J; del Muro JG; Esteller M; Sánchez-Carbayo M
Clin Cancer Res; 2008 Dec; 14(24):8236-43. PubMed ID: 19088041
[TBL] [Abstract][Full Text] [Related]
20. Quantitative promoter hypermethylation analysis of cancer-related genes in salivary gland carcinomas: comparison with methylation-specific PCR technique and clinical significance.
Lee ES; Issa JP; Roberts DB; Williams MD; Weber RS; Kies MS; El-Naggar AK
Clin Cancer Res; 2008 May; 14(9):2664-72. PubMed ID: 18451230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
